Werewolf Therapeutics’ (HOWL) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Werewolf Therapeutics (NASDAQ:HOWL) in a research report sent to investors on Monday morning, Benzinga reports. HC Wainwright currently has a $15.00 price target on the stock. HC Wainwright also issued estimates for Werewolf Therapeutics’ Q2 2024 earnings at ($0.40) EPS, Q3 2024 earnings at ($0.36) EPS, Q4 2024 earnings at ($0.37) EPS, FY2024 earnings at ($1.52) EPS, FY2025 earnings at ($0.91) EPS, FY2026 earnings at ($1.11) EPS, FY2027 earnings at ($1.89) EPS and FY2028 earnings at ($1.34) EPS.

Separately, JMP Securities began coverage on shares of Werewolf Therapeutics in a report on Wednesday, April 3rd. They issued a mkt outperform rating and a $12.00 target price for the company.

Werewolf Therapeutics Price Performance

Shares of NASDAQ HOWL opened at $5.48 on Monday. The stock has a market capitalization of $237.56 million, a PE ratio of -5.03 and a beta of 0.71. Werewolf Therapeutics has a fifty-two week low of $1.57 and a fifty-two week high of $8.19. The company has a debt-to-equity ratio of 0.29, a current ratio of 7.14 and a quick ratio of 7.14. The business has a fifty day moving average price of $6.12 and a two-hundred day moving average price of $4.73.

Werewolf Therapeutics (NASDAQ:HOWL) last released its earnings results on Thursday, March 7th. The company reported ($0.33) EPS for the quarter, beating the consensus estimate of ($0.43) by $0.10. The firm had revenue of $1.50 million for the quarter, compared to analyst estimates of $2.75 million. Werewolf Therapeutics had a negative net margin of 256.33% and a negative return on equity of 36.43%. As a group, equities analysts predict that Werewolf Therapeutics will post -1.38 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Werewolf Therapeutics

A number of hedge funds have recently modified their holdings of the business. Financial Perspectives Inc boosted its holdings in Werewolf Therapeutics by 80.0% in the fourth quarter. Financial Perspectives Inc now owns 6,750 shares of the company’s stock valued at $26,000 after acquiring an additional 3,000 shares during the last quarter. Certuity LLC acquired a new stake in Werewolf Therapeutics during the fourth quarter worth approximately $39,000. Lighthouse Investment Partners LLC bought a new stake in shares of Werewolf Therapeutics in the 4th quarter valued at $87,000. Denali Advisors LLC bought a new stake in Werewolf Therapeutics in the first quarter valued at $172,000. Finally, PFM Health Sciences LP raised its stake in Werewolf Therapeutics by 35.6% during the 4th quarter. PFM Health Sciences LP now owns 3,468,177 shares of the company’s stock worth $13,387,000 after buying an additional 909,895 shares during the period. Institutional investors and hedge funds own 64.84% of the company’s stock.

Werewolf Therapeutics Company Profile

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.